Evergy, Inc.
EVRG
is set to release first-quarter 2021 results on May 6, before the market opens. In the last reported quarter, the company delivered an earnings surprise of 40%.
Let’s discuss the factors that are likely to get reflected in the upcoming quarterly results.
Factors to Consider
Steady demand from residential customers and gradual reopening of economic activities are likely to have increased the demand from commercial and industrial customers. Consequently, results for the first quarter are also likely to get a boost.
Evergy’s cost-management initiatives and extreme cold weather conditions in its service territories during February are likely to have positively impacted first-quarter earnings.
Expectation
The Zacks Consensus Estimate for first-quarter earnings per share is pegged at 47 cents, indicating a 14.6% increase from the year-ago reported figure.
Quantitative Model Prediction
Our proven model does not conclusively predict an earnings beat for Evergy this time around. The combination of a positive
Earnings ESP
and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here as you will see below.
Earnings ESP
: Its Earnings ESP is 0.00%.
You can uncover the best stocks to buy or sell before they’re reported with our
Earnings ESP Filter
.
Zacks Rank
: Evergy currently holds a Zacks Rank #3.
Stocks to Consider
Here are some players from the same
industry
that are worth considering, as these have the right combination of elements to deliver an earnings beat in the upcoming releases.
Ameresco, Inc.
AMRC
is set to release first-quarter results on May 4. It has an Earnings ESP of +6.54% and a Zacks Rank #3. You can see
the complete list of today’s Zacks #1 Rank stocks here
.
Ormat Technologies Inc.
ORA
is set to release first-quarter results on May 5. It has an Earnings ESP of +6.54% and a Zacks Rank #3.
Chesapeake Energy Corporation
CHK
is set to release first-quarter results on May 11. It has an Earnings ESP of +110.96% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report